{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T06:52:24Z","timestamp":1791269544304,"version":"4.1.0"},"reference-count":191,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1016\/j.jconrel.2013.01.032","type":"journal-article","created":{"date-parts":[[2013,2,8]],"date-time":"2013-02-08T05:16:18Z","timestamp":1360300578000},"page":"175-188","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":168,"title":["Biomedical applications of bisphosphonates"],"prefix":"10.1016","volume":"167","author":[{"given":"Elisabeth V.","family":"Giger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastien","family":"Castagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Christophe","family":"Leroux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2013.01.032_bb0005","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/bcr414","article-title":"Development of bisphosphonates","volume":"4","author":"Fleisch","year":"2002","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0010","first-page":"804","article-title":"Pharmacist Theodor Salzer (1833\u20131900) and the discovery of bisphosphonates","volume":"66","author":"Petroianu","year":"2011","journal-title":"Pharmazie"},{"key":"10.1016\/j.jconrel.2013.01.032_bb0015","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1152\/ajplegacy.1962.203.4.671","article-title":"Isolation from urine of pyrophosphate, a calcification inhibitor","volume":"203","author":"Fleisch","year":"1962","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0020","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/212901a0","article-title":"Effect of pyrophosphate on hydroxyapatite and its implications in calcium homeostasis","volume":"212","author":"Fleisch","year":"1966","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2013.01.032_bb0025","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0021-9258(19)77302-5","article-title":"A soluble ribonucleic acid intermediate in protein synthesis","volume":"231","author":"Hoagland","year":"1958","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0030","first-page":"10-10A","article-title":"The influence of pyrophosphate analogues (diphosphonates) on the precipitation and dissolution of calcium phosphate in vitro and in vivo","volume":"2","author":"Fleisch","year":"1968","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0035","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1126\/science.165.3899.1262","article-title":"Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo","volume":"165","author":"Fleisch","year":"1969","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2013.01.032_bb0040","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1126\/science.165.3899.1264","article-title":"Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo","volume":"165","author":"Francis","year":"1969","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2013.01.032_bb0045","first-page":"2","article-title":"Historical perspectives on the clinical development of bisphosphonates in the treatment of bone diseases","volume":"7","author":"Francis","year":"2007","journal-title":"J. Musculoskelet. Neuronal Interact."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0050","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S0140-6736(69)92293-4","article-title":"Diphosphonates in the treatment of myositis ossificans","volume":"18","author":"Bassett","year":"1969","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2013.01.032_bb0055","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.bone.2005.05.003","article-title":"Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite","volume":"38","author":"Nancollas","year":"2006","journal-title":"Bone"},{"key":"10.1016\/j.jconrel.2013.01.032_bb0060","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00198-007-0540-8","article-title":"Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy","volume":"19","author":"Russell","year":"2008","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0065","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1126\/science.289.5484.1508","article-title":"Therapeutic approaches to bone diseases","volume":"289","author":"Rodan","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2013.01.032_bb0070","doi-asserted-by":"crossref","first-page":"3710","DOI":"10.1002\/anie.200500350","article-title":"A dendritic tetra(bisphosphonic acid) for improved targeting of proteins to bone","volume":"44","author":"Bansal","year":"2005","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0075","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1021\/bc040249w","article-title":"Development of a rhenium-186-labeled MAG3-conjugated bisphosphonate for the palliation of metastatic bone pain based on the concept of bifunctional radiopharmaceuticals","volume":"16","author":"Ogawa","year":"2005","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0080","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.bmc.2009.12.041","article-title":"Design, synthesis, and biological evaluation of novel estradiol\u2013bisphosphonate conjugates as bone-specific estrogens","volume":"18","author":"Morioka","year":"2010","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0085","doi-asserted-by":"crossref","first-page":"9217","DOI":"10.1016\/j.bmc.2008.09.010","article-title":"Bisphosphonated fluoroquinolone esters as osteotropic prodrugs for the prevention of osteomyelitis","volume":"16","author":"Tanaka","year":"2008","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0090","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1097\/00005344-200311000-00014","article-title":"Systemic depletion of macrophages by liposomal bisphosphonates reduces neointimal formation following balloon-injury in the rat carotid artery","volume":"42","author":"Danenberg","year":"2003","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0095","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1161\/01.CIR.0000023532.98469.48","article-title":"Macrophage depletion by clodronate-containing liposomes reduces neointimal formation after balloon injury in rats and rabbits","volume":"106","author":"Danenberg","year":"2002","journal-title":"Circ. Res."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0100","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1080\/17453670810016768","article-title":"Local application of zoledronic acid incorporated in a poly(d, l-lactide)-coated implant accelerates fracture healing in rats","volume":"79","author":"Greiner","year":"2008","journal-title":"Acta Orthop."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0105","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/j.jbiomech.2009.03.024","article-title":"Prediction of bone density around orthopedic implants delivering bisphosphonate","volume":"42","author":"Stadelmann","year":"2009","journal-title":"J. Biomech."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0110","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1006\/jcis.2001.7500","article-title":"Nonpolymeric coatings of iron oxide colloids for biological use as magnetic resonance imaging contrast agents","volume":"238","author":"Portet","year":"2001","journal-title":"J. Colloid Interface Sci."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0115","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/adhm.201200088","article-title":"siRNA transfection with calcium phosphate nanoparticles stabilized with PEGylated chelators","volume":"2","author":"Giger","year":"2013","journal-title":"Adv. Healthcare Mater."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0120","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1021\/bc100483k","article-title":"99mTc-bisphosphonate-iron oxide nanoparticle conjugates for dual-modality biomedical imaging","volume":"22","author":"Torres Martin de Rosales","year":"2011","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0125","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s10334-008-0161-z","article-title":"Imaging E-selectin expression following traumatic brain injury in the rat using a targeted USPIO contrast agent","volume":"22","author":"Chapon","year":"2009","journal-title":"Magn. Reson. Mater. Phys. Biol. Med."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0130","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1172\/JCI115539","article-title":"Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure","volume":"88","author":"Sato","year":"1991","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0135","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1124\/mol.105.020776","article-title":"Cytosolic entry of bisphosphonate drugs requires acidification of vesicles after fluid-phase endocytosis","volume":"69","author":"Thompson","year":"2006","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0140","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1083\/jcb.101.6.2210","article-title":"Cell-mediated extracellular acidification and bone resorption: evidence for a low pH in resorbing lacunae and localization of a 100-kD lysosomal membrane protein at the osteoclast ruffled border","volume":"101","author":"Baron","year":"1985","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0145","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1126\/science.2528207","article-title":"Osteoclastic bone resorption by a polarized vacuolar proton pump","volume":"245","author":"Blair","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2013.01.032_bb0150","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1359\/jbmr.1997.12.9.1358","article-title":"Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5\u2032-(\u03b2, \u03b3-dichloromethylene) triphosphate, by mammalian cells in vitro","volume":"12","author":"Frith","year":"1997","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0155","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0026-895X(24)12222-5","article-title":"Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP\/ATP translocase by a nonhydrolyzable, adenine-containing metabolite","volume":"61","author":"Lehenkari","year":"2002","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0160","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1006\/bbrc.1999.1499","article-title":"Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates","volume":"264","author":"van Beek","year":"1999","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0165","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1359\/jbmr.1998.13.4.581","article-title":"Nitrogen-containing biphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras","volume":"13","author":"Luckman","year":"1998","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0170","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0022-3565(24)38786-5","article-title":"Structure\u2013activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates","volume":"296","author":"Dunford","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0175","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1359\/jbmr.2000.15.8.1467","article-title":"Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298","volume":"15","author":"Coxon","year":"2000","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0180","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.coph.2006.03.005","article-title":"Recent advances in understanding the mechanism of action of bisphosphonates","volume":"6","author":"Coxon","year":"2006","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0185","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1359\/jbmr.060118","article-title":"Inhibition of protein prenylation by bisphosphonates causes sustained activation of Rac, Cdc42, and Rho GTPases","volume":"21","author":"Dunford","year":"2006","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0190","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/sj.bjp.0706628","article-title":"A new endogenous ATP analog (ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen-containing bisphosphonates","volume":"147","author":"M\u00f6nkk\u00f6nen","year":"2006","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0195","doi-asserted-by":"crossref","first-page":"6941","DOI":"10.1016\/j.biomaterials.2005.04.059","article-title":"Effects of bisphosphonates on proliferation and osteoblast differentiation of human bone marrow stromal cells","volume":"26","author":"von Knoch","year":"2005","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2013.01.032_bb0200","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.bone.2010.08.008","article-title":"Novel actions of bisphosphonates in bone: preservation of osteoblast and osteocyte viability","volume":"49","author":"Bellido","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.jconrel.2013.01.032_bb0205","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.canlet.2007.07.007","article-title":"Bisphosphonates in cancer therapy","volume":"257","author":"Stresing","year":"2007","journal-title":"Cancer Lett."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0210","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1038\/sj.bjc.6600297","article-title":"The bisphosphonate zoledronic acid impairs membrane localisation and induces cytochrome c release in breast cancer cells","volume":"86","author":"Senaratne","year":"2002","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jconrel.2013.01.032_bb0215","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.bone.2010.09.035","article-title":"Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase","volume":"48","author":"Stresing","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.jconrel.2013.01.032_bb0220","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1124\/jpet.102.035295","article-title":"Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid","volume":"302","author":"Wood","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0225","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0169-409X(00)00061-2","article-title":"Administration routes and delivery systems of bisphosphonates for the treatment of bone resorption","volume":"42","author":"Ezra","year":"2000","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0230","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1002\/jps.2600831218","article-title":"On the absorption of alendronate in rats","volume":"83","author":"Lin","year":"1994","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0235","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(02)08827-X","article-title":"Treatment of postmenopausal osteoporosis","volume":"359","author":"Delmas","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2013.01.032_bb0240","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ijpharm.2010.08.041","article-title":"Absorption and safety of alendronate, a nitrogen-containing bisphosphonate, after intrapulmonary administration in rats","volume":"400","author":"Katsumi","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0245","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1002\/jbmr.147","article-title":"Development of a novel transdermal patch of alendronate, a nitrogen-containing bisphosphonate, for the treatment of osteoporosis","volume":"25","author":"Kusamori","year":"2010","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0250","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1023\/A:1018981832261","article-title":"Intranasal delivery of the bisphosphonate alendronate in the rat and dog","volume":"10","author":"Sutton","year":"1993","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0255","doi-asserted-by":"crossref","first-page":"3783","DOI":"10.1002\/jps.22620","article-title":"Development of polyethylene glycol-conjugated alendronate, a novel nitrogen-containing bisphosphonate derivative: evaluation of absorption, safety, and effects after intrapulmonary administration in rats","volume":"100","author":"Katsumi","year":"2011","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0260","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S0885-3924(03)00252-5","article-title":"Safety of subcutaneous clodronate and efficacy in hypercalcemia of malignancy: a novel route of administration","volume":"26","author":"Roemer-B\u00e9cuwe","year":"2003","journal-title":"J. Pain Symptom Manage."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0265","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.bone.2011.01.014","article-title":"Pharmacology of bisphosphonates","volume":"49","author":"Cremers","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.jconrel.2013.01.032_bb0270","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1210\/jc.2009-1947","article-title":"Long-term use of bisphosphonates in osteoporosis","volume":"95","author":"Watts","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0275","first-page":"270","article-title":"The use of whole-body retention of Tc-99m diphosphonate in the diagnosis of metabolic bone disease","volume":"19","author":"Fogelman","year":"1978","journal-title":"Br. Med. J."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0280","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/S0140-6736(71)91447-4","article-title":"Diphosphonates and Paget's disease of bone","volume":"297","author":"Smith","year":"1971","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2013.01.032_bb0285","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1136\/bmj.295.6609.1301","article-title":"Paget's disease of bone: early and late responses to three different modes of treatment with aminohydroxypropylidene bisphosphonate (APD)","volume":"295","author":"Harinck","year":"1987","journal-title":"Br. Med. J."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0290","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.bone.2010.09.002","article-title":"Bisphosphonates in Paget's disease","volume":"49","author":"Reid","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.jconrel.2013.01.032_bb0295","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1185\/030079908X260899","article-title":"A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5mg","volume":"24","author":"Abelson","year":"2008","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0300","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s001980050224","article-title":"Interim report and recommendations of the World Health Organization Task-Force for Osteoporosis","volume":"10","author":"Genant","year":"1999","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0305","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/BF02405341","article-title":"Preliminary observations of a form of coherence therapy for osteoporosis","volume":"36","author":"Anderson","year":"1984","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0310","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/cpt1976205593","article-title":"Etidronate disodium in postmenopausal osteoporosis","volume":"20","author":"Heaney","year":"1976","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0315","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1056\/NEJM199005033221803","article-title":"Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis","volume":"322","author":"Storm","year":"1990","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0320","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1056\/NEJM199511303332201","article-title":"Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis","volume":"333","author":"Liberman","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0325","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0330","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","article-title":"Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis","volume":"19","author":"Chesnut","year":"2004","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0335","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.jconrel.2013.01.032_bb0340","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa011807","article-title":"Intravenous zoledronic acid in postmenopausal women with low bone mineral density","volume":"346","author":"Reid","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0345","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00198-006-0274-z","article-title":"Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study","volume":"18","author":"Silverman","year":"2007","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0350","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1185\/03007995.2011.643296","article-title":"Bisphosphonate therapy for osteoporosis: combining optimal fracture risk reduction with patient preference","volume":"28","author":"Beard","year":"2012","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0355","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/qjmed\/hcq259","article-title":"Bisphosphonates for post-menopausal osteoporosis: are they all the same?","volume":"104","author":"Rizzoli","year":"2011","journal-title":"QJM"},{"key":"10.1016\/j.jconrel.2013.01.032_bb0360","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1056\/NEJMcp1012926","article-title":"Glucocorticoid-induced bone disease","volume":"365","author":"Weinstein","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0365","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1749-6632.2010.05766.x","article-title":"The use of bisphosphonates in cancer treatment","volume":"1218","author":"Coleman","year":"2011","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0370","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1056\/NEJMcp042806","article-title":"Hypercalcemia associated with cancer","volume":"352","author":"Stewart","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0375","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1093\/annonc\/mdm442","article-title":"Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel","volume":"19","author":"Aapro","year":"2008","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0380","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1542\/peds.111.3.573","article-title":"Intravenous bisphosphonate therapy in children with osteogenesis imperfecta","volume":"111","author":"Falk","year":"2003","journal-title":"Pediatrics"},{"key":"10.1016\/j.jconrel.2013.01.032_bb0385","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1530\/EJE-08-0282","article-title":"Management of osteoporosis in children","volume":"159","author":"Shaw","year":"2008","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0390","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1359\/JBMR.051006","article-title":"Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta","volume":"21","author":"DiMeglio","year":"2006","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0395","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/pbc.22681","article-title":"The use of zoledronic acid in pediatric cancer patients","volume":"56","author":"August","year":"2011","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.jconrel.2013.01.032_bb0400","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/jor.20317","article-title":"Addition of bisphosphonate to antibiotic and anti-inflammatory treatment reduces bone resorption in experimental Staphylococcus aureus-induced arthritis","volume":"25","author":"Verdrengh","year":"2007","journal-title":"J. Orthop. Res."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0405","doi-asserted-by":"crossref","first-page":"12282","DOI":"10.1073\/pnas.0702760104","article-title":"Disrupting antibiotic resistance propagation by inhibiting the conjugative DNA relaxase","volume":"104","author":"Lujan","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0410","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1111\/j.1365-2591.2005.01021.x","article-title":"Assessment of a gel-type chelating preparation containing 1-hydroxyethylidene-1, 1-bisphosphonate","volume":"38","author":"Girard","year":"2005","journal-title":"Int. Endod. J."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0415","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.bone.2008.01.003","article-title":"Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis","volume":"42","author":"Rizzoli","year":"2008","journal-title":"Bone"},{"key":"10.1016\/j.jconrel.2013.01.032_bb0420","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1359\/jbmr.0707onj","article-title":"Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research","volume":"22","author":"Khosla","year":"2007","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0425","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1010650","article-title":"Bisphosphonate use and atypical fractures of the femoral shaft","volume":"364","author":"Schilcher","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0430","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1056\/NEJMoa1001086","article-title":"Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur","volume":"362","author":"Black","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0435","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1093\/annonc\/mdj105","article-title":"Management of the adverse effects associated with intravenous bisphosphonates","volume":"17","author":"Tanvetyanon","year":"2006","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0440","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.bone.2011.01.003","article-title":"Safety of bisphosphonates","volume":"49","author":"Pazianas","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.jconrel.2013.01.032_bb0445","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s00223-010-9364-1","article-title":"Adverse effects of bisphosphonates","volume":"86","author":"Abrahamsen","year":"2010","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0450","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1111\/j.1440-1754.2011.02391.x","article-title":"Nephrocalcinosis: a potential complication of bisphosphonate therapy in children","volume":"47","author":"Jensen","year":"2011","journal-title":"J. Paediatr. Child Health"},{"key":"10.1016\/j.jconrel.2013.01.032_bb0455","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1016\/0006-2952(93)90328-T","article-title":"Importance of the paracellular pathway for the transport of a new bisphosphonate using the human CACO-2 monolayers model","volume":"46","author":"Boulenc","year":"1993","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0460","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/BF01623002","article-title":"Clinical pharmacology of alendronate sodium","volume":"3","author":"Gertz","year":"1993","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0465","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/BF02556218","article-title":"Sodium EDTA enhances intestinal absorption of two bisphosphonates","volume":"49","author":"Janner","year":"1991","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0470","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1021\/jm980645y","article-title":"A peptide prodrug approach for improving bisphosphonate oral absorption","volume":"43","author":"Ezra","year":"2000","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0475","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.ejps.2010.06.020","article-title":"Particulate adducts based on sodium risedronate and titanium dioxide for the bioavailability enhancement of oral administered bisphosphonates","volume":"41","author":"Dissette","year":"2010","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0480","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3109\/10611861003667599","article-title":"Alendronate-loaded microparticles for improvement of intestinal cellular absorption","volume":"19","author":"Baek","year":"2011","journal-title":"J. Drug Target."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0485","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1023\/B:PHAM.0000012150.60180.e3","article-title":"Effect of chitosan on epithelial cell tight junctions","volume":"21","author":"Smith","year":"2004","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0490","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.ejps.2012.04.002","article-title":"Improved oral bioavailability of alendronate via the mucoadhesive liposomal delivery system","volume":"46","author":"Han","year":"2012","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0495","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/j.2042-7158.2010.01229.x","article-title":"Positively-charged microemulsion for improving the oral bioavailability of alendronate: in-vitro and in-vivo assessment","volume":"63","author":"Meng","year":"2011","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0500","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1517\/17425247.3.5.685","article-title":"Promoting absorption of drugs in humans using medium-chain fatty acid-based solid dosage forms: GIPET\u2122","volume":"3","author":"Leonard","year":"2006","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0505","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1208\/s12248-011-9307-4","article-title":"Absorption enhancers: applications and advances","volume":"14","author":"Aungst","year":"2012","journal-title":"AAPS J."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0510","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1007\/s11095-008-9542-2","article-title":"Mechanistic analysis of chemical permeation enhancers for oral drug delivery","volume":"25","author":"Whitehead","year":"2008","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0515","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1002\/jps.23136","article-title":"Development of a novel self-dissolving microneedle array of alendronate, a nitrogen-containing bisphosphonate: evaluation of transdermal absorption, safety, and pharmacological effects after application in rats","volume":"101","author":"Katsumi","year":"2012","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0520","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1023\/A:1018981832261","article-title":"Intranasal delivery of the bisphosphonate alendronate in the rat and dog","volume":"10","author":"Sutton","year":"1993","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0525","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jconrel.2011.02.030","article-title":"Formulation and in vivo evaluation of sodium alendronate spray-dried microparticles intended for lung delivery","volume":"152","author":"Cruz","year":"2011","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2013.01.032_bb0530","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1080\/03639040500528871","article-title":"Formulation and in vitro evaluation of bisphosphonate loaded microspheres for implantation in osteolysis","volume":"32","author":"Samdancioglu","year":"2006","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0535","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1208\/pt020310","article-title":"Long-term release of clodronate from biodegradable microspheres","volume":"2","author":"Perugini","year":"2001","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.jconrel.2013.01.032_bb0540","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/jbm.b.31933","article-title":"Development of an injectable two-phase drug delivery system for sequential release of antiresorptive and osteogenic drugs","volume":"100B","author":"Zou","year":"2011","journal-title":"J. Biomed. Mater. Res. B"},{"key":"10.1016\/j.jconrel.2013.01.032_bb0545","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1002\/adma.200306340","article-title":"Chemically modified calcium phosphates as novel materials for bisphosphonate delivery","volume":"16","author":"Josse","year":"2004","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0550","doi-asserted-by":"crossref","first-page":"7776","DOI":"10.1016\/j.biomaterials.2010.06.047","article-title":"In vivo bone augmentation in an osteoporotic environment using bisphosphonate-loaded calcium deficient apatite","volume":"31","author":"Verron","year":"2010","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2013.01.032_bb0555","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1088\/0957-4484\/22\/3\/035102","article-title":"Bisphosphonate-modified gold nanoparticles: a useful vehicle to study the treatment of osteonecrosis of the femoral head","volume":"22","author":"Fanord","year":"2011","journal-title":"Nanotechnology"},{"key":"10.1016\/j.jconrel.2013.01.032_bb0560","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1359\/jbmr.060817","article-title":"Retention, distribution, and effects of intraosseously administered ibandronate in the infarcted femoral head","volume":"22","author":"Aya-ay","year":"2007","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0565","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/jbm.a.33165","article-title":"Binding affinity of surface functionalized gold nanoparticles to hydroxyapatite","volume":"99A","author":"Ross","year":"2011","journal-title":"J. Biomed. Mater. Res. A"},{"key":"10.1016\/j.jconrel.2013.01.032_bb0570","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/S0008-6363(00)00304-7","article-title":"Inhibition by leukocyte depletion of neointima formation after balloon angioplasty in a rabbit model of restenosis","volume":"49","author":"Miller","year":"2001","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0575","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jconrel.2010.03.011","article-title":"Physicochemical parameters affecting liposomal bisphosphonates bioactivity for restenosis therapy: internalization, cell inhibition, activation of cytokines and complement, and mechanism of cell death","volume":"146","author":"Epstein-Barash","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2013.01.032_bb0580","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jconrel.2006.03.010","article-title":"Alendronate-loaded nanoparticles deplete monocytes and attenuate restenosis","volume":"113","author":"Cohen-Sela","year":"2006","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2013.01.032_bb0585","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.jconrel.2011.11.037","article-title":"Liposomal alendronate for the treatment of restenosis","volume":"161","author":"Gutman","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2013.01.032_bb0590","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1093\/humrep\/den375","article-title":"Peritoneal macrophage depletion by liposomal bisphosphonate attenuates endometriosis in the rat model","volume":"24","author":"Haber","year":"2009","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0595","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1093\/rheumatology\/40.9.978","article-title":"Suppression of chronic streptococcal cell wall-induced arthritis in Lewis rats by liposomal clodronate","volume":"40","author":"Richards","year":"2001","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jconrel.2013.01.032_bb0600","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.jconrel.2010.08.030","article-title":"Route of administration-dependent anti-inflammatory effect of liposomal alendronate","volume":"148","author":"Haber","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2013.01.032_bb0605","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.jconrel.2008.06.016","article-title":"Dendritic multishell architectures for drug and dye transport","volume":"132","author":"Quadir","year":"2008","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2013.01.032_bb0610","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/sj.bjc.6603240","article-title":"Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach","volume":"95","author":"Zeisberger","year":"2006","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jconrel.2013.01.032_bb0615","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1158\/0008-5472.CAN-09-2995","article-title":"Blockade of tumor necrosis factor alpha signaling in tumor-associated macrophages as a radiosensitizing strategy","volume":"70","author":"Meng","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0620","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.nano.2011.03.004","article-title":"Nanotechnologies to use bisphosphonates as potent anticancer agents: the effects of zoledronic acid encapsulated into liposomes","volume":"7","author":"Marra","year":"2011","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2013.01.032_bb0625","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.ijpharm.2010.10.046","article-title":"Self-assembly nanoparticles for the delivery of bisphosphonates into tumors","volume":"403","author":"Salzano","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0630","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.biotechadv.2011.06.018","article-title":"New self-assembly nanoparticles and stealth liposomes for the delivery of zoledronic acid: a comparative study","volume":"30","author":"Marra","year":"2012","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0635","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jconrel.2010.04.028","article-title":"Delivery of zoledronic acid encapsulated in folate-targeted liposome results in potent in vitro cytotoxic activity on tumor cells","volume":"146","author":"Shmeeda","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2013.01.032_bb0640","doi-asserted-by":"crossref","first-page":"10020","DOI":"10.1039\/c0cp02034f","article-title":"A multimodal magnetic resonance imaging nanoplatform for cancer theranostics","volume":"13","author":"Benyettou","year":"2011","journal-title":"Phys. Chem. Chem. Phys."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0645","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s004410050963","article-title":"Age-related differences in the temporal and spatial regulation of matrix metalloproteinases (MMPs) in normal skin and acute cutaneous wounds of healthy humans","volume":"290","author":"Ashcroft","year":"1997","journal-title":"Cell Tissue Res."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0650","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1016\/j.biomaterials.2007.12.043","article-title":"Attenuation of protease activity in chronic wound fluid with bisphosphonate-functionalised hydrogels","volume":"29","author":"Rayment","year":"2008","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2013.01.032_bb0655","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1302\/0301-620X.76B6.7983118","article-title":"Does early micromotion of femoral stem prostheses matter? 4-7-Year stereoradiographic follow-up of 84 cemented prostheses","volume":"76-B","author":"Karrholm","year":"1994","journal-title":"J. Bone Joint Surg. Br."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0660","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.bbrc.2011.08.057","article-title":"Effect of heparin and alendronate coating on titanium surfaces on inhibition of osteoclast and enhancement of osteoblast function","volume":"413","author":"Moon","year":"2011","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0665","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s10856-011-4539-5","article-title":"Local bisphosphonate release versus hydroxyapatite coating for stainless steel screw fixation in rat tibiae","volume":"23","author":"Agholme","year":"2012","journal-title":"J. Mater. Sci. Mater. Med."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0670","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1016\/j.biomaterials.2008.12.025","article-title":"The effect of surface immobilized bisphosphonates on the fixation of hydroxyapatite-coated titanium implants in ovariectomized rats","volume":"30","author":"Gao","year":"2009","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2013.01.032_bb0675","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.bone.2004.10.004","article-title":"Calcium phosphate drug delivery system: influence of local zoledronate release on bone implant osteointegration","volume":"36","author":"Peter","year":"2005","journal-title":"Bone"},{"key":"10.1016\/j.jconrel.2013.01.032_bb0680","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s10856-005-0625-x","article-title":"Bacterial adhesion to bisphosphonate coated hydroxyapatite","volume":"16","author":"Ganguli","year":"2005","journal-title":"J. Mater. Sci. Mater. Med."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0685","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1007\/s10529-011-0542-7","article-title":"Co-loading of bisphosphonates and antibiotics to a biomimetic hydroxyapatite coating","volume":"33","author":"Forsgren","year":"2011","journal-title":"Biotechnol. Lett."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0690","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1016\/S0142-9612(01)00010-2","article-title":"Bisphosphonate derivatized polyurethanes resist calcification","volume":"22","author":"Alferiev","year":"2001","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2013.01.032_bb0695","doi-asserted-by":"crossref","first-page":"5509","DOI":"10.1002\/anie.201007894","article-title":"Synthesis of 64CuII\u2013bis(dithiocarbamatebisphosphonate) and its conjugation with superparamagnetic iron oxide nanoparticles: in vivo evaluation as dual-modality PET\u2013MRI agent","volume":"50","author":"Torres Martin de Rosales","year":"2011","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0700","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jconrel.2010.11.012","article-title":"Gene delivery with bisphosphonate-stabilized calcium phosphate nanoparticles","volume":"150","author":"Giger","year":"2011","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2013.01.032_bb0705","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1039\/b801911h","article-title":"Bis-phosphonates-ultra small superparamagnetic iron oxide nanoparticles: a platform towards diagnosis and therapy","author":"Lalatonne","year":"2008","journal-title":"Chem. Commun."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0710","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1039\/C005286H","article-title":"Multimodal superparamagnetic nanoplatform for clinical applications: immunoassays, imaging & therapy","volume":"149","author":"Motte","year":"2011","journal-title":"Faraday Discuss."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0715","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1021\/bc034090j","article-title":"Synthesis and evaluation of water-soluble polymeric bone-targeted drug delivery systems","volume":"14","author":"Wang","year":"2003","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0720","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1002\/anie.200805133","article-title":"Targeting bone metastases with a bispecific anticancer and antiangiogenic polymer\u2013alendronate\u2013taxane conjugate","volume":"48","author":"Miller","year":"2009","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0725","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1021\/bp0200447","article-title":"Targeting systemically administered proteins to bone by bisphosphonate conjugation","volume":"18","author":"Uludag","year":"2002","journal-title":"Biotechnol. Prog."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0730","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1021\/mp050017u","article-title":"Imparting mineral affinity to fetuin by bisphosphonate conjugation: a comparison of three bisphosphonate conjugation schemes","volume":"2","author":"Gittens","year":"2005","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0735","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1021\/bm070121s","article-title":"Synthesis and in vitro hydroxyapatite binding of peptides conjugated to calcium-binding moieties","volume":"8","author":"Murphy","year":"2007","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.jconrel.2013.01.032_bb0740","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jconrel.2011.09.096","article-title":"Synthesis, characterization and evaluation of bone targeting salmon calcitonin analogs in normal and osteoporotic rats","volume":"158","author":"Bhandari","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2013.01.032_bb0745","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/jbm.a.34002","article-title":"Bisphosphonate-decorated lipid nanoparticles designed as drug carriers for bone diseases","volume":"100A","author":"Wang","year":"2012","journal-title":"J. Biomed. Mater. Res. A"},{"key":"10.1016\/j.jconrel.2013.01.032_bb0750","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3109\/10611869808995866","article-title":"Osteotropic drug delivery system (ODDS) based on bisphosphonic prodrug. IV Effects of osteotropic estradiol on bone mineral density and uterine weight in ovariectomized rats","volume":"5","author":"Fujisaki","year":"1997","journal-title":"J. Drug Target."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0755","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/jbmr.5650080407","article-title":"High-dose estrogen inhibits bone resorption and stimulates bone formation in the ovariectomized mouse","volume":"8","author":"Bain","year":"1993","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0760","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1056\/NEJM199506153322401","article-title":"The use of estrogens and progestins and the risk of breast cancer in postmenopausal women","volume":"332","author":"Colditz","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0765","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1007\/s002239900104","article-title":"Effect of 17\u03b2-estradiol\u2013bisphosphonate conjugates, potential bone-seeking estrogen pro-drugs, on 17\u03b2-estradiol serum kinetics and bone mass in rats","volume":"59","author":"Bauss","year":"1996","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0770","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1016\/j.bmc.2012.01.024","article-title":"Design and synthesis of novel bone-targeting dual-action pro-drugs for the treatment and reversal of osteoporosis","volume":"20","author":"Arns","year":"2012","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0775","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1021\/mp2001445","article-title":"Dendritic poly(ethylene glycol) bearing paclitaxel and alendronate for targeting bone neoplasms","volume":"8","author":"Clementi","year":"2011","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0780","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1053\/j.semnuclmed.2009.10.003","article-title":"Systemic metabolic radiopharmaceutical therapy in the treatment of metastatic bone pain","volume":"40","author":"Paes","year":"2010","journal-title":"Semin. Nucl. Med."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0785","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1007\/s00259-008-0841-y","article-title":"EANM procedure guideline for treatment of refractory metastatic bone pain","volume":"35","author":"Bodei","year":"2008","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.jconrel.2013.01.032_bb0790","first-page":"646","article-title":"Pharmacokinetics of rhenium-186 after administration of rhenium-186-HEDP to patients with bone metastases","volume":"33","author":"de Klerk","year":"1992","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0795","first-page":"122","article-title":"Therapeutic effects of a 186Re-complex-conjugated bisphosphonate for the palliation of metastatic bone pain in an animal model","volume":"48","author":"Ogawa","year":"2007","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0800","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1021\/bc100071k","article-title":"188Re(CO)3-dipicolylamine-alendronate: a new bisphosphonate conjugate for the radiotherapy of bone metastases","volume":"21","author":"Torres Martin de Rosales","year":"2010","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0805","doi-asserted-by":"crossref","first-page":"4789","DOI":"10.1016\/j.bmcl.2008.07.092","article-title":"An osteoclast-targeting agent for imaging and therapy of bone metastasis","volume":"18","author":"Liu","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0810","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.bone.2010.03.006","article-title":"A promising approach for treatment of tumor-induced bone diseases: utilizing bisphosphonate derivatives of nucleoside antimetabolites","volume":"47","author":"Reinholz","year":"2010","journal-title":"Bone"},{"key":"10.1016\/j.jconrel.2013.01.032_bb0815","doi-asserted-by":"crossref","first-page":"7502","DOI":"10.1021\/jm300493m","article-title":"Development of novel bisphosphonate prodrugs of doxorubicin for targeting bone metastases that are cleaved pH dependently or by cathepsin B: synthesis, cleavage properties, and binding properties to hydroxyapatite as well as bone matrix","volume":"55","author":"Hochdorffer","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0820","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1007\/s00259-008-0728-y","article-title":"Re-188-labelled gemcitabine\/bisphosphonate (Gem\/BP): a multi-functional, bone-specific agent as a potential treatment for bone metastases","volume":"35","author":"El-Mabhouh","year":"2008","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.jconrel.2013.01.032_bb0825","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1021\/jm0105326","article-title":"Osteoadsorptive bisphosphonate derivatives of fluoroquinolone antibacterials","volume":"45","author":"Herczegh","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0830","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.ejmech.2011.10.049","article-title":"Synthesis of osteotropic hydroxybisphosphonate derivatives of fluoroquinolone antibacterials","volume":"47","author":"McPherson","year":"2012","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0835","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1002\/bjs.4644","article-title":"Bisphosphonate\u2013ciprofloxacin bound to Skelite\u2122 is a prototype for enhancing experimental local antibiotic delivery to injured bone","volume":"91","author":"Buxton","year":"2004","journal-title":"Br. J. Surg."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0840","doi-asserted-by":"crossref","first-page":"6955","DOI":"10.1021\/jm801007z","article-title":"Linking bisphosphonates to the free amino groups in fluoroquinolones: preparation of osteotropic prodrugs for the prevention of osteomyelitis","volume":"51","author":"Houghton","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0845","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.biomaterials.2005.06.012","article-title":"A comparison of mineral affinity of bisphosphonate\u2013protein conjugates constructed with disulfide and thioether linkages","volume":"27","author":"Wright","year":"2006","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2013.01.032_bb0850","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1023\/B:PHAM.0000022407.05163.01","article-title":"Impact of tether length on bone mineral affinity of protein\u2013bisphosphonate conjugates","volume":"21","author":"Gittens","year":"2004","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0855","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1021\/bc700196q","article-title":"Ligand-modified aminobisphosphonate for linking proteins to hydroxyapatite and bone surface","volume":"19","author":"Ehrick","year":"2007","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0860","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1113\/expphysiol.1993.sp003721","article-title":"Osteoclast function and its control","volume":"78","author":"Zaidi","year":"1993","journal-title":"Exp. Physiol."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0865","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ijpharm.2010.04.015","article-title":"Synthesis, characterization and in vitro evaluation of a bone targeting delivery system for salmon calcitonin","volume":"394","author":"Bhandari","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0870","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1038\/nm.2665","article-title":"Directing mesenchymal stem cells to bone to augment bone formation and increase bone mass","volume":"18","author":"Guan","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0875","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1021\/mp800003u","article-title":"Biodistribution and pharmacokinetic studies of bone-targeting N-(2-hydroxypropyl)methacrylamide copolymer\u2013alendronate conjugates","volume":"5","author":"Pan","year":"2008","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0880","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1021\/mp200083n","article-title":"Antiangiogenic antitumor activity of HPMA copolymer\u2013paclitaxel\u2013alendronate conjugate on breast cancer bone metastasis mouse model","volume":"8","author":"Miller","year":"2011","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0885","doi-asserted-by":"crossref","first-page":"4450","DOI":"10.1016\/j.biomaterials.2011.02.059","article-title":"Enhanced anti-tumor activity and safety profile of targeted nano-scaled HPMA copolymer\u2013alendronate\u2013TNP-470 conjugate in the treatment of bone malignances","volume":"32","author":"Segal","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2013.01.032_bb0890","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2217\/17435889.4.2.161","article-title":"A novel biomaterial for osteotropic drug nanocarriers: synthesis and biocompatibility evaluation of a PLGA\u2013ALE conjugate","volume":"4","author":"Pignatello","year":"2009","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2013.01.032_bb0895","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1016\/j.biomaterials.2007.12.022","article-title":"Biocompatibility of poly(d, l-lactide-co-glycolide) nanoparticles conjugated with alendronate","volume":"29","author":"Cenni","year":"2008","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2013.01.032_bb0900","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jconrel.2007.06.003","article-title":"Design of surface-modified poly(d, l-lactide-co-glycolide) nanoparticles for targeted drug delivery to bone","volume":"122","author":"Choi","year":"2007","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2013.01.032_bb0905","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jconrel.2011.11.020","article-title":"Bone metastasis targeting: a novel approach to reach bone using zoledronate anchored PLGA nanoparticle as carrier system loaded with docetaxel","volume":"158","author":"Chaudhari","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2013.01.032_bb0910","doi-asserted-by":"crossref","first-page":"7164","DOI":"10.1016\/j.biomaterials.2012.06.026","article-title":"Alendronate coated poly-lactic-co-glycolic acid (PLGA) nanoparticles for active targeting of metastatic breast cancer","volume":"33","author":"Thamake","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2013.01.032_bb0915","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jconrel.2011.09.098","article-title":"The journey of a drug-carrier in the body: an anatomo-physiological perspective","volume":"161","author":"Bertrand","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2013.01.032_bb0920","doi-asserted-by":"crossref","first-page":"4101","DOI":"10.1002\/adfm.201102357","article-title":"Targeting efficiency and biodistribution of zoledronate conjugated docetaxel loaded pegylated PBCA nanoparticles for bone metastasis","volume":"22","author":"Chaudhari","year":"2012","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0925","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ijpharm.2006.11.024","article-title":"Bone targeting potential of bisphosphonate-targeted liposomes: preparation, characterization and hydroxyapatite binding in vitro","volume":"331","author":"Hengst","year":"2007","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0930","doi-asserted-by":"crossref","first-page":"4148","DOI":"10.1016\/j.bmcl.2009.05.117","article-title":"Synthesis of calcium phosphate-binding liposome for drug delivery","volume":"19","author":"Anada","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0935","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1039\/b801750f","article-title":"Isolation of calcium phosphate crystals from complex biological fluids using bisphosphonate-modified superparamagnetic beads","author":"Hernandez-Santana","year":"2008","journal-title":"Chem. Commun."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0940","doi-asserted-by":"crossref","first-page":"13358","DOI":"10.1021\/ja0651355","article-title":"A biocompatible method of decorporation: bisphosphonate-modified magnetite nanoparticles to remove uranyl ions from blood","volume":"128","author":"Wang","year":"2006","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0945","series-title":"Bisphosphonic compounds for preventing or limiting fixing of macromolecules, microorganisms and biofilm on solid, in particular metal or mineral surfaces, US2008\/0220037A1","author":"Denizot","year":"2008"},{"key":"10.1016\/j.jconrel.2013.01.032_bb0950","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1359\/JBMR.040305","article-title":"A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women","volume":"19","author":"Bekker","year":"2004","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.jconrel.2013.01.032_bb0955","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nrd3705","article-title":"Bench to bedside: elucidation of the OPG\u2013RANK\u2013RANKL pathway and the development of denosumab","volume":"11","author":"Lacey","year":"2012","journal-title":"Nat. Rev. Drug Discov."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365913000692?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365913000692?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T15:28:12Z","timestamp":1759159692000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365913000692"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":191,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["S0168365913000692"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2013.01.032","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2013,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biomedical applications of bisphosphonates","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2013.01.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}